Prognostic Value of (18)F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

BACKGROUND AND AIM: The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Contrast Media Mol Imaging
Autors principals: Quaquarini, E., D'Ambrosio, D., Sottotetti, F., Gallivanone, F., Hodolic, M., Baiardi, P., Palumbo, R., Vellani, C., Canevari, C., Bernardo, A., Castiglioni, I., Porta, C., Trifirò, G.
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6458948/
https://ncbi.nlm.nih.gov/pubmed/31049043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/4325946
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars